Holen Sie sich die Stockscreener-App
99.45
2.06%
2.01
Handel nachbörslich:
99.45
Schlusskurs vom Vortag:
$97.44
Offen:
$98.14
24-Stunden-Volumen:
1.58M
Relative Volume:
0.81
Marktkapitalisierung:
$20.25B
Einnahmen:
$7.68B
Nettoeinkommen (Verlust:
$903.80M
KGV:
22.35
EPS:
4.45
Netto-Cashflow:
$1.14B
1W Leistung:
+2.59%
1M Leistung:
-10.19%
6M Leistung:
-5.01%
1J Leistung:
-18.16%
1-Tages-Spanne:
$98.14
$101.00
1-Wochen-Bereich:
$93.10
$101.00
52-Wochen-Spanne:
$93.10
$123.96
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Vergleichen Sie ZBH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
99.45 | 20.25B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
129.84 | 224.94B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
98.92 | 140.88B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
357.11 | 132.32B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.75 | 107.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.46 | 41.71B | 5.72B | 4.17B | 259.90M | 6.97 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect - MSN
What to Expect From Zimmer Biomet's Next Quarterly Earnings Report - MSN
Zimmer Biomet's SWOT analysis: medical device maker's stock faces ERP hurdles - MSN
Zimmer acquires Paragon 28 in $1.2bn deal - Yahoo Finance
Is Zimmer Biomet Holdings, Inc. (ZBH) The Top Falling Stock with Unusual Volume? - Insider Monkey
Zimmer Biomet Holdings (ZBH) Completes Merger with Paragon 28 - GuruFocus
Paragon 28 concludes merger with Zimmer Biomet subsidiary By Investing.com - Investing.com South Africa
Paragon 28 concludes merger with Zimmer Biomet subsidiary - Investing.com
Zimmer Biomet completes Paragon 28 acquisition - MassDevice
What To Expect From Zimmer Biomet's Next Quarterly Earnings Report - Barchart.com
Zimmer Biomet Closes Paragon 28 Acquisition - marketscreener.com
Zimmer Biomet Completes Acquisition of Paragon 28 | ZBH Stock News - GuruFocus
Zimmer Biomet Completes Acquisition Of Paragon 28 - marketscreener.com
Zimmer Biomet Completes Acquisition of Paragon 28 - PR Newswire
Knee Replacement Market Detailed In New Research Report 2025 | - openPR.com
Maxillofacial surgery Market Projected To Witness Substantial - openPR.com
Bone Replacement Products Market Projected To Witness - openPR.com
Zimmer Biomet Hits 34th 52-Week Low: Value Play Or Value Trap? - Barchart.com
Zimmer Biomet stock touches 52-week low at $97.62 By Investing.com - Investing.com Canada
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Zimmer Biomet stock touches 52-week low at $97.62 - Investing.com
Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga
Zimmer Biomet (ZBH) Receives Price Target Boost Amid MedTech Sec - GuruFocus
Is the Market Bullish or Bearish on Zimmer Biomet Holdings? - Benzinga
Zimmer Biomet Holdings (NYSE:ZBH) Proposes Officer Exculpation Amendment at Upcoming Shareholder Meeting - Yahoo
SEC Form DEFA14A filed by Zimmer Biomet Holdings Inc. - Quantisnow
Zimmer Biomet granted CE Mark for RibFix Advantage Fixation System - MSN
Price Over Earnings Overview: Zimmer Biomet HoldingsZimmer Biomet Holdings (NYSE:ZBH) - Benzinga
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Zimmer Biomet (ZBH): Buy, Sell, Or Hold Post Q4 Earnings? - Barchart.com
Zimmer Biomet Announces Webcast and Conference Call of First Qua - GuruFocus
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results - The Malaysian Reserve
Zimmer Biomet First Quarter Earnings: Key Financial Results Coming May 5 - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
An Intrinsic Calculation For Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Suggests It's 39% Undervalued - simplywall.st
ZBH Stock to Gain From Volume Growth Amid Rising Costs - TradingView
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Evercore ISI Adjusts Zimmer Biomet Holdings' Price Target to $116 From 110, Maintains In Line Rating - MarketScreener
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by UniSuper Management Pty Ltd - MarketBeat
Zimmer Biomet Gets CE Mark Approval for RibFix Advantage Fixation System - MarketScreener
Zimmer Biomet wins CE Mark for RibFix Advantage (ZBH:NYSE) - Seeking Alpha
Zimmer Biomet wins CE mark for rib fixation system - MassDevice
Zimmer Biomet Receives CE Mark Approval For Ribfix Advantage® Fixation System - MarketScreener
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System – Company Announcement - Financial Times
Groundbreaking Rib Fixation Technology Gets Historic European ApprovalZimmer Biomet Leads Innovation - Stock Titan
Providence Capital Advisors LLC Buys 2,800 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - MarketBeat
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Zimmer Biomet Holdings (NYSE:ZBH) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Corebridge Financial Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - MarketBeat
Zimmer Biomet Stock Price | ZBH Stock Quote, News, and History - markets.businessinsider.com
Just Three Days Till Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Will Be Trading Ex-Dividend - simplywall.st
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):